No abstract available.
Humans ; Interferon-alpha* ; Prednisolone*

No abstract available.
Child* ; Hepatitis, Chronic* ; Humans ; Interferon-alpha*

No abstract available.
Humans ; Interferon-alpha* ; Interferons* ; Melanoma* ; Ulcer*

No abstract available.
Female ; Granulosa Cells* ; Interferon-alpha* ; Rodentia*

No abstract available.
Child* ; Hepatitis B, Chronic* ; Hepatitis, Chronic* ; Humans ; Interferon-alpha*

Kaposi's sarcoma (KS) is a lympho-angioproliferative disease, with four variants; one of which is classical KS (CKS). Classical KS is clinically characterized by single or multiple pea-sized bluish-red macules on the distal portions of the lower extremities. A 60-year-old man presented with an asymptomatic, solitary patch on the left sole. He had been successfully treated for the classical type of Kaposi sarcoma on the right sole with interferon-alpha 3 years before. The patient was treated with six million units of interferon-alpha three times per week for 6 months. The lesion showed complete resolution and there has been no report of recurrence for 1 year after treatment.
Humans ; Interferon-alpha ; Lower Extremity ; Middle Aged ; Recurrence ; Sarcoma, Kaposi

Classic Kaposi's sarcoma is a multicentric neoplastic tumor of endothelial cell origin and has a relatively benign course even if extracutaneous sites are involved. We report a case of classic Kaposi's sarcoma of a 68-year-old man who had tender, reddish nodules and purplish papules and macules on the right sole. The biopsy specimen showed typical findings consistent with Kaposi's sarcoma such as endothelial cell proliferation, spindle cells forming slit like spaces occupied by red blood cells and positive staining with CD 34 antibody in the endothelial cells. The patient was treated with six million units of interferon alfa three times per week for 6 months. Four months after a 6 month treatment course, histopathological findings on the resolving lesion didn't show any evidence of Kaposi's sarcoma.
Aged ; Biopsy ; Endothelial Cells ; Erythrocytes ; Humans ; Interferon-alpha* ; Sarcoma, Kaposi*

Interferon-alpha is known to inhibit the vascular endothelial cell proliferation and migration in vitro.It has been used systemically for the treatment of choroidal neovascular membrane proliferation.However, significant side effects in systemic administration limit the dosage and duration of its use. It has been suggested that reducing systemic side effects and maintenance of high intraocular concentration would be achieved with the direct intravitreal injection of Interferon-alpha.Thus, this study was undertaken to estimate the toxicity and safe dose of Interferon-alpha when it is given intravitreally in rabbits. Normal saline, Interferon-alpha 50, 000IU, 100, 000IU, 200, 000IU and 300, 000 IU were given intravitreally to 10 rabbit eyes.Toxicity was assessed by serial ERGs after 7 and 14 days.Animals were sacrificed at 14 days after injection for histopathologic study. The ERG was flattened at 14 days in 300, 000IU of Interferon-alpha group.On histologic examination, inflammatory reaction of vitreous and retina remained at an insignificant level upto 200, 000IU, but increased in dose dependent manner above this dose, resulting in prominent reaction in 300, 000IU group. Therefore, we suggest that 200, 000IU of Interferon-alpha may be the safe dose when administered intravitreally in rabbits, and 300, 000IU may be the toxic dose.
Choroid ; Endothelial Cells ; Interferon-alpha ; Intravitreal Injections ; Membranes ; Rabbits* ; Retina

No abstract available.
Interferon-alpha* ; Interleukin-2* ; Killer Cells, Lymphokine-Activated*

Hypereosinophilic syndrome is a multisystem disorder with unexplained persistent eosinophilia and marked preference for systemic organ involvement. More than half of all patients have cutaneous involvement, usually presenting as angioedema, urticarial lesions, and eczematous, pruriginous papules. Hypereosinophilic syndrome presenting with generalized cutaneous blisters is rare, and we report the findings of a patient who was successfully treated with interferon-alpha.
Angioedema ; Blister* ; Eosinophilia ; Humans ; Hypereosinophilic Syndrome* ; Interferon-alpha